---
layout: default
title: Panitumumab
parent: 僅模型預測 (L5)
nav_order: 292
evidence_level: L5
indication_count: 2
---

# Panitumumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# PANITUMUMAB: From Metastatic Colorectal Cancer to Drug-Induced Osteoporosis

## One-Sentence Summary

> Panitumumab is a known anti-EGFR monoclonal antibody, believed to be originally used for RAS wild-type metastatic colorectal cancer (this cannot be confirmed from the evidence pack, as `original_indications` and `original_moa` are both data gaps).
> The TxGNN model predicts it may be effective for **Drug-Induced Osteoporosis**,
> but currently **no clinical trials** and **no publications** support this direction — the prediction is model-output only.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not extractable from regulatory data (0 licenses, drug not marketed in Germany). Publicly known context suggests RAS wild-type metastatic colorectal cancer, but this is unverified against this evidence pack |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.13% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on the rationale accompanying this prediction, panitumumab is understood to be an anti-EGFR monoclonal antibody. EGFR signaling has some basic-research relevance to osteoclast/osteoblast differentiation, but this is an indirect, non-specific pathway link — there is no literature demonstrating that EGFR inhibition treats drug-induced osteoporosis. If anything, published safety data on EGFR-inhibitor drug classes tends to focus on monitoring bone density risk during long-term use, not on therapeutic benefit for bone disease.

A second candidate indication in this evidence pack, severe nonproliferative diabetic retinopathy, shows the same pattern: its pathology is primarily VEGF-driven, not EGFR-driven, and anti-EGFR agents are actually associated with known ocular toxicities (conjunctivitis, trichomegaly, keratitis) rather than protective effects.

Given the absence of any clinical trial or literature evidence for either prediction, the high TxGNN score should be interpreted as a knowledge-graph association rather than a validated therapeutic mechanism — most likely a false-positive signal arising from indirect pathway crosstalk (e.g., EGFR–MAPK/PI3K overlap with VEGF signaling) rather than a genuine repurposing opportunity.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Germany Market Information

Panitumumab is not currently marketed in Germany (0 authorizations, no license records available in this evidence pack).

---

## Cytotoxicity

Panitumumab is an anti-EGFR monoclonal antibody used in oncology, so this section is included based on its known drug class.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody, non-cytotoxic mechanism) |
| Myelosuppression Risk | Low — mAb-class EGFR inhibitors are not typically myelosuppressive; please refer to the package insert warnings and precautions for confirmation |
| Emetogenicity Classification | Low — consistent with monoclonal antibody agents generally |
| Monitoring Items | Infusion-related reactions, dermatologic toxicity, serum electrolytes (magnesium/calcium, a known class effect of EGFR inhibitors), renal function |
| Handling Protection | Please refer to institutional hazardous drug handling policy; many oncology monoclonal antibodies are classified as hazardous drugs (e.g., NIOSH list) despite non-cytotoxic mechanism |

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: `TFDA 仿單警語/禁忌` is flagged as a **Blocking** data gap — DG001. This must be resolved before this candidate can proceed to S1 safety evaluation.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Both predicted indications are L5 (model prediction only), with zero supporting clinical trials or literature, and the proposed mechanistic links are indirect and speculative. In addition, a Blocking data gap (missing TFDA label warnings/contraindications) prevents this candidate from entering safety pre-screening (S1) at all.

**To proceed, the following is needed:**
- Resolve DG001 (TFDA label warnings/contraindications) — Blocking, required before any S1 safety evaluation
- Resolve DG002 (confirmed MOA from DrugBank) — needed for mechanistic plausibility assessment
- Confirm actual original indication(s) via authoritative regulatory source (original_indications field is currently empty)
- Monitor for emerging clinical trials or literature on EGFR-pathway involvement in bone metabolism or diabetic retinopathy before reconsidering evidence level
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

